FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588118428> ?p ?o ?g. }

• W2588118428 abstract "Background: The significance of eosinophilia after allogeneic stem cell transplantation (SCT) is presently unknown. The eosinophil activation pathway involves Th2 cytokines and thus eosinophilia after PBSCT may reflect Th2 pathway activation. Previous data suggest that blood eosinophilia precedes or coincides with the development of acute or chronic graft-verus-host disease (aGVHD or cGVHD). In a recent report, Aisa et al reported that patients with peripheral eosinophilia within 100 days post-SCT had a superior overall survival (OS) and transplant-related mortality (TRM) along with a lower incidence of cGVHD compared to those who did not (Transplant Int 2007). Methods: A retrospective analysis of 237 recipients who received allogeneic PBSC from related donors at PMH was performed (myeloablative:reduced intensity conditioning 162:75). The present study evaluated the impact of early (before day 100: EEo) or late onset (beyond day 100: LEo) eosinophilia (≥0.5x109/L in peripheral blood) on transplant outcomes after allogeneic PBSCT. The patient population included 237 recipients of allogeneic PBSC from related donors (male:female 137:100, median age 51 years-old). Results: Biphasic pattern of eosinophilia with 2 peaks before day 100 and beyond day 100 was observed after PBSCT. The cumulative incidence of early onset eosinophilia was 43% at day 100. EEo was not associated with the development of grade 3–4 aGVHD (p=0.1), but there was a trend in the development of grade 2–4 aGVHD (p=0.053). In univariate analyses, the group with EEo showed favorable OS (p=0.002), TRM (p=0.05) and a lower relapse incidence (p=0.05) compared to those without EEo but did not have improved GVHD-specific survival (GSS). EEo did not predict the grade of aGVHD or response to steroid therapy for aGVHD. EEo was significantly associated with the development of late onset eosinophilia (p=0.000004 by chi-square test, p=0.00007 by McNemar test). The cumulative incidence of LEo was 62% at 2 years with median onset of 1 year after SCT. There was an association with the onset of cutaneous (p=0.001), oral (p=0.04), ocular (p=0.02) or pulmonary cGVHD (p=0.03). In univariate analyses, with median follow-up durations of 773 days (patients with LEo) and 679 days (patients without LEo), significant differences were observed in favor of those with LEo in terms of 3 year OS (86% vs 41%, p=0.00000000005), TRM at 3 years (10% vs 37%, p=0.000003), 3 year relapse rate (11% vs 31%, p=0.00003) and 3-year GSS (90% vs 64%, p=0.00001). In multivariate analyses, the LEo, rather than EEo, was identified as a significant favorable prognostic factor for OS (p=0.000006, hazard ratio [HR] 0.21), TRM (p=0.0006, HR 0.24), relapse incidence (p=0.003, HR 0.28) and GSS (p=0.001, HR 0.26). Conclusion: The late onset eosinophilia (beyond day 100), not EEo, seemed to have an important prognostic implication for outcome after allogeneic PBSCT. Further studies are warranted to validate its prognostic impact on SCT outcomes. Figure 1. Comparisonof overall survival (A) and GVHD-specific survival (B) between patients with and without late onset eosinophilia after allogeneic PBSCT Figure 1. Comparisonof overall survival (A) and GVHD-specific survival (B) between patients with and without late onset eosinophilia after allogeneic PBSCT" @default.
• W2588118428 created "2017-02-24" @default.
• W2588118428 creator A5014346242 @default.
• W2588118428 creator A5021987793 @default.
• W2588118428 creator A5026397928 @default.
• W2588118428 creator A5032888224 @default.
• W2588118428 creator A5042152459 @default.
• W2588118428 creator A5067214379 @default.
• W2588118428 creator A5083858828 @default.
• W2588118428 date "2007-11-16" @default.
• W2588118428 modified "2023-09-28" @default.
• W2588118428 title "Late Onset Eosinophilia (beyond Day 100), Rather Than Early Onset Eosinophilia, Has a Significant Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT)." @default.
• W2588118428 doi "https://doi.org/10.1182/blood.v110.11.1062.1062" @default.
• W2588118428 hasPublicationYear "2007" @default.
• W2588118428 type Work @default.
• W2588118428 sameAs 2588118428 @default.
• W2588118428 citedByCount "0" @default.
• W2588118428 crossrefType "journal-article" @default.
• W2588118428 hasAuthorship W2588118428A5014346242 @default.
• W2588118428 hasAuthorship W2588118428A5021987793 @default.
• W2588118428 hasAuthorship W2588118428A5026397928 @default.
• W2588118428 hasAuthorship W2588118428A5032888224 @default.
• W2588118428 hasAuthorship W2588118428A5042152459 @default.
• W2588118428 hasAuthorship W2588118428A5067214379 @default.
• W2588118428 hasAuthorship W2588118428A5083858828 @default.
• W2588118428 hasConcept C120665830 @default.
• W2588118428 hasConcept C121332964 @default.
• W2588118428 hasConcept C126322002 @default.
• W2588118428 hasConcept C203014093 @default.
• W2588118428 hasConcept C2776042228 @default.
• W2588118428 hasConcept C2777037409 @default.
• W2588118428 hasConcept C2777129736 @default.
• W2588118428 hasConcept C2777408962 @default.
• W2588118428 hasConcept C2779972918 @default.
• W2588118428 hasConcept C2911091166 @default.
• W2588118428 hasConcept C61511704 @default.
• W2588118428 hasConcept C71924100 @default.
• W2588118428 hasConcept C88879693 @default.
• W2588118428 hasConcept C90924648 @default.
• W2588118428 hasConceptScore W2588118428C120665830 @default.
• W2588118428 hasConceptScore W2588118428C121332964 @default.
• W2588118428 hasConceptScore W2588118428C126322002 @default.
• W2588118428 hasConceptScore W2588118428C203014093 @default.
• W2588118428 hasConceptScore W2588118428C2776042228 @default.
• W2588118428 hasConceptScore W2588118428C2777037409 @default.
• W2588118428 hasConceptScore W2588118428C2777129736 @default.
• W2588118428 hasConceptScore W2588118428C2777408962 @default.
• W2588118428 hasConceptScore W2588118428C2779972918 @default.
• W2588118428 hasConceptScore W2588118428C2911091166 @default.
• W2588118428 hasConceptScore W2588118428C61511704 @default.
• W2588118428 hasConceptScore W2588118428C71924100 @default.
• W2588118428 hasConceptScore W2588118428C88879693 @default.
• W2588118428 hasConceptScore W2588118428C90924648 @default.
• W2588118428 hasLocation W25881184281 @default.
• W2588118428 hasOpenAccess W2588118428 @default.
• W2588118428 hasPrimaryLocation W25881184281 @default.
• W2588118428 hasRelatedWork W1955322177 @default.
• W2588118428 hasRelatedWork W2020231398 @default.
• W2588118428 hasRelatedWork W2028757239 @default.
• W2588118428 hasRelatedWork W2066519436 @default.
• W2588118428 hasRelatedWork W2125926317 @default.
• W2588118428 hasRelatedWork W2142493118 @default.
• W2588118428 hasRelatedWork W2360260519 @default.
• W2588118428 hasRelatedWork W2543872697 @default.
• W2588118428 hasRelatedWork W2588118428 @default.
• W2588118428 hasRelatedWork W2614629048 @default.
• W2588118428 isParatext "false" @default.
• W2588118428 isRetracted "false" @default.
• W2588118428 magId "2588118428" @default.
• W2588118428 workType "article" @default.